PresSura

PresSura (also known as EU-C-001 or RO-0671721) is a selective, small-molecule neurokinin-1 (NK1) receptor antagonist originally developed by Roche and licensed to Eustralis Pharmaceuticals (trading as PresSura Neuro). The drug is designed to target neurogenic inflammation, restore blood-brain barrier integrity, and control elevated intracranial pressure (ICP) following traumatic brain injury (TBI). By blocking the binding of substance P to the NK1 receptor, PresSura prevents the vascular leakage and vasogenic edema that typically follow brain trauma. It is currently in Phase 2 clinical development for moderate-to-severe TBI and is also being explored for concussion-related conditions (such as post-concussion syndrome and chronic traumatic encephalopathy) and stroke.

Other names

N-(3,5-bis-trifluoromethylbenzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide